Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1002388/000100238813000040/accl-2013930x10qsinglesour.htm
April 2014
February 2014
January 2014
December 2013
December 2013
October 2013
September 2013
July 2013
July 2013
June 2013
• | Acquisition of ChemSW, a leader in environmental health and safety compliance solutions, furthering Accelrys' scientific innovation lifecycle management and sustainability strategies by providing solutions for managing and tracking the source, use and disposal of chemicals along the entire lab-to-plant value chain. |
• | Launch of Accelrys Insight and Accelrys Insight for Excel, completing the roll-out of Accelrys' next-generation cheminformatics suite and providing an interactive, collaborative environment for rapid and effective decision-making in drug discovery. |
• | Availability of Accelrys’ integrated Predictive Sciences solutions, enabling drug discovery teams to investigate and evaluate hypotheses about the chemical or biological behavior of molecules of therapeutic interest in silico prior to costly experimentation. |
• | Launch of Discovery Studio 4.0, the latest release of Accelrys Discovery Studio and a key component of Accelrys’ Predictive Sciences solutions. The software contains the only available commercial version of the widely used CHARMM (Chemistry at Harvard Macromolecular Mechanics) program for molecular dynamics simulation and analysis. The developers of CHARMM were awarded the Nobel Prize in Chemistry this month and Accelrys retains exclusive rights to its commercial use. |
• | Hosted the Accelrys Life Sciences Symposium in London, a gathering of leading global life sciences customers, including representatives from BT, GlaxoSmithKline, Medimmune and Merz. |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1002388/000100238813000040/accl-2013930x10qsinglesour.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Accelrys, Inc..
Accelrys, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:
Ticker: ACCL
CIK: 1002388
Form Type: 10-Q Quarterly Report
Accession Number: 0001002388-13-000040
Submitted to the SEC: Thu Oct 31 2013 5:03:35 PM EST
Accepted by the SEC: Thu Oct 31 2013
Period: Monday, September 30, 2013
Industry: Prepackaged Software